



LIVINGSTONE HEALTH HOLDINGS LIMITED

(Incorporated in the Republic of Singapore)
(Company Registration Number 200404283C)

EXERCISE OF WARRANTS

The board of directors (“**Board**” or “**Directors**”) of Livingstone Health Holdings Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) refers to the announcements made by the Company in relation to the Rights cum Warrants Issue on 27 March 2024, 30 April 2024, 13 May 2024, 30 May 2024, 11 June 2024, 2 July 2024, 4 July 2024, 1 August 2024, 30 August 2024, 3 September 2024, 5 September 2024, 6 September 2024, 18 September 2024, 23 September 2024, 25 September 2024, 30 September 2024, 7 October 2024 and 15 October 2024 (the “**Announcements**”). Unless otherwise defined, all terms and references used herein shall bear the same meanings ascribed to them in the Announcements.

Further to the Announcements, the Board is pleased to announce that 1,034,078 new ordinary shares in the capital of the Company (“**New Shares**”) have been allotted and issued by the Company today pursuant to the exercise of Warrants as set out in the Deed Poll.

The New Shares will rank *pari passu* in all respects with the existing shares of the Company (“**Shares**”), except that they will not rank for any dividends, rights, allotments or other distributions that may be declared or paid, the record date for which falls before the date of issue of the Warrants.

Following the allotment and issuance of the New Shares, the total number of issued and paid-up ordinary share capital of the Company has increased to 614,315,905 Shares.

The New Shares are expected to be listed and quoted on Catalist on or about 29 October 2024 and the trading of the New Shares is expected to commence with effect from 9.00 am on the same day.

By Order of the Board

Dr Tay Ching Yit, Wilson
Executive Director and Chief Executive Officer
24 October 2024

*This announcement has been reviewed by the Company’s sponsor, SAC Capital Private Limited (the “**Sponsor**”). This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited (“**SGX-ST**”) and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.*

The contact person for the Sponsor is Ms Lee Khai Yinn (Telephone: (65) 6232 3210) at 1 Robinson Road, #21-00, AIA Tower, Singapore 048542.